https://peptidesciencedaily.com Independent, cited reporting on peptide research, trials, regulation, and safety. Not medical advice. en Sun, 23 Aug 2026 09:00:00 GMT https://peptidesciencedaily.com/research/mazdutide-us-phase-2-obesity-trial-lancet https://peptidesciencedaily.com/research/mazdutide-us-phase-2-obesity-trial-lancet Sun, 23 Aug 2026 09:00:00 GMT A phase 2, placebo-controlled trial conducted at 24 US centers found once-weekly mazdutide produced dose-dependent weight loss of up to 18.1 percent over 32 weeks, the first published US population data for the GLP-1/glucagon dual agonist, which is approved in China but remains investigational in the United States. https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-08-23 https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-08-23 Sun, 23 Aug 2026 09:00:00 GMT New PubMed literature from August 17 through August 23, 2026 included a phase 3 trial of the glucagon/GLP-1 dual agonist survodutide in obesity, a phase 2 US trial of mazdutide, a meta-analysis and a biomarker study on cagrilintide and retatrutide, a pediatric trial of dulaglutide in thalassemia-induced diabetes, three papers on bone-building peptides, a basic-science paper identifying a new antimicrobial function for the mitochondrial peptide MOTS-c, and smaller items on GHK-Cu, octreotide, and semaglutide. https://peptidesciencedaily.com/research/pioneer-teens-oral-semaglutide-pediatric-type-2-diabetes-results https://peptidesciencedaily.com/research/pioneer-teens-oral-semaglutide-pediatric-type-2-diabetes-results Fri, 21 Aug 2026 09:00:00 GMT ClinicalTrials.gov posted the complete results of PIONEER TEENS on August 21, 2026, the first phase 3 trial of an oral GLP-1 therapy in children and adolescents with type 2 diabetes. The 132-participant trial found oral semaglutide reduced HbA1c more than placebo over 52 weeks. Novo Nordisk has said it plans to seek regulatory approval in this age group but oral semaglutide is not currently approved for pediatric use. https://peptidesciencedaily.com/research/achieve-j-orforglipron-japan-diabetes-safety-trial https://peptidesciencedaily.com/research/achieve-j-orforglipron-japan-diabetes-safety-trial Wed, 19 Aug 2026 09:00:00 GMT The phase 3 trial, tracking three doses of the oral GLP-1 receptor agonist over a year in 401 participants, found gastrointestinal side effects and treatment discontinuation rose with dose but reported no severe hypoglycemia. https://peptidesciencedaily.com/research/select-trial-semaglutide-hscrp-inflammation-analysis https://peptidesciencedaily.com/research/select-trial-semaglutide-hscrp-inflammation-analysis Tue, 18 Aug 2026 09:00:00 GMT A prespecified secondary analysis of the SELECT cardiovascular outcomes trial found semaglutide reduced high-sensitivity C-reactive protein by nearly 38 percent, with the change linked to lower risk of major cardiovascular events independent of weight loss. The findings were published August 18, 2026 in Circulation. https://peptidesciencedaily.com/research/step-12-semaglutide-chinese-adults-phase-3b-lancet https://peptidesciencedaily.com/research/step-12-semaglutide-chinese-adults-phase-3b-lancet Tue, 11 Aug 2026 09:00:00 GMT A phase 3b randomized trial conducted at 19 sites in mainland China and Taiwan found once-weekly semaglutide 2.4 mg produced significantly greater weight loss than placebo, using BMI thresholds defined locally for Chinese and Taiwanese populations. The results were published August 10, 2026 in The Lancet Diabetes & Endocrinology. https://peptidesciencedaily.com/research/semaglutide-select-dementia-risk-proteomic-signature https://peptidesciencedaily.com/research/semaglutide-select-dementia-risk-proteomic-signature Mon, 10 Aug 2026 09:00:00 GMT A post hoc analysis of the phase 3 SELECT cardiovascular outcomes trial found that semaglutide slowed the rise of a validated 25-protein blood test that predicts 5- and 20-year dementia risk, compared with placebo. The analysis was published August 8, 2026 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-08-09 https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-08-09 Sun, 09 Aug 2026 09:00:00 GMT New PubMed literature from August 2 through August 8, 2026 included four papers on kisspeptin and reproductive-axis signaling, a mediation analysis separating survodutide's liver effects from its weight-loss effects, a multi-drug review of GLP-1 receptor agonists in dialysis patients, a network meta-analysis and a cost-effectiveness review on the bone-building peptide teriparatide, and smaller items on a peptide-coated antibiotic nanoparticle, real-world radionuclide therapy outcomes, and a small case series on gut peptide drugs for constipation. https://peptidesciencedaily.com/research/semaglutide-select-flow-soul-pooled-kidney-outcomes-lancet https://peptidesciencedaily.com/research/semaglutide-select-flow-soul-pooled-kidney-outcomes-lancet Sat, 08 Aug 2026 09:00:00 GMT A prespecified pooled analysis of participant-level data from the SELECT, FLOW, and SOUL randomized trials, covering more than 30,000 people, found semaglutide reduced a composite of kidney failure, major kidney function loss, and kidney- or cardiovascular-related death. The analysis was published August 7, 2026 in The Lancet Diabetes & Endocrinology. https://peptidesciencedaily.com/research/bmj-tirzepatide-cardiovascular-outcomes-cohort-study https://peptidesciencedaily.com/research/bmj-tirzepatide-cardiovascular-outcomes-cohort-study Thu, 06 Aug 2026 09:00:00 GMT A population-based cohort of nearly 53,000 people with type 2 diabetes and existing atherosclerotic heart disease found fewer heart attacks, strokes, and deaths among tirzepatide users than among those started on sitagliptin. The study and an accompanying editorial were published August 5, 2026 in The BMJ. https://peptidesciencedaily.com/research/mazdutide-orforglipron-jama-phase-3-trials https://peptidesciencedaily.com/research/mazdutide-orforglipron-jama-phase-3-trials Tue, 04 Aug 2026 09:00:00 GMT GLORY-2 found once-weekly mazdutide produced substantially greater weight loss than placebo in Chinese adults with obesity, while ACHIEVE-5 found oral orforglipron added to titrated insulin glargine improved glycemic control in type 2 diabetes. Both randomized trials, along with an editorial comparing them, were published August 4, 2026 in JAMA. https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-08-02 https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-08-02 Sun, 02 Aug 2026 09:00:00 GMT New PubMed literature from July 26 through August 1, 2026 included four mechanistic and real-world studies on the bone-building peptides teriparatide and abaloparatide, real-world and post hoc data on tirzepatide and CagriSema, an animal study on orforglipron's effect on aortic aneurysm, two papers on kisspeptin and reproductive-axis signaling, and safety or detection work touching desmopressin, BPC-157, and AOD-9604. https://peptidesciencedaily.com/research/zenagamtide-amycretin-phase-2-type-2-diabetes-lancet https://peptidesciencedaily.com/research/zenagamtide-amycretin-phase-2-type-2-diabetes-lancet Fri, 31 Jul 2026 09:00:00 GMT Two companion Phase 2 trials of subcutaneous and oral zenagamtide, the investigational GLP-1 and amylin receptor agonist formerly known as amycretin, were published July 30, 2026 in The Lancet, reporting dose-dependent A1C reductions in adults with type 2 diabetes. https://peptidesciencedaily.com/research/oral-semaglutide-alcohol-use-disorder-trial https://peptidesciencedaily.com/research/oral-semaglutide-alcohol-use-disorder-trial Wed, 29 Jul 2026 09:00:00 GMT A 50-person, placebo-controlled trial published in The American Journal of Psychiatry missed its primary craving endpoint but found semaglutide significantly cut heavy drinking days, drinks per drinking day, and alcohol-related consequences. https://peptidesciencedaily.com/news/retatrutide-triumph-2-triumph-3-phase-3-results https://peptidesciencedaily.com/news/retatrutide-triumph-2-triumph-3-phase-3-results Sun, 26 Jul 2026 09:00:00 GMT TRIUMPH-2 tested the investigational triple agonist in adults with type 2 diabetes and obesity, while TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease. Both trials met their weight-loss goals; a cardiovascular-event analysis in TRIUMPH-3 did not reach statistical significance. https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-07-26 https://peptidesciencedaily.com/research/this-week-in-peptide-research-2026-07-26 Sun, 26 Jul 2026 09:00:00 GMT A week of new PubMed literature brought dueling papers on activating versus blocking the GIP receptor for weight loss, fresh evidence on bone-building peptides, safety analyses touching retatrutide and weight-loss drugs generally, and a formal regulatory profile of orforglipron following its April 2026 approval. https://peptidesciencedaily.com/news/fda-advisory-panel-recommends-six-peptides-compounding-july-2026 https://peptidesciencedaily.com/news/fda-advisory-panel-recommends-six-peptides-compounding-july-2026 Sat, 25 Jul 2026 09:00:00 GMT The Pharmacy Compounding Advisory Committee voted over two days to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for the Section 503A bulk drug substances list, and voted against emideltide. The votes are advisory and non-binding, and the FDA had not announced a final decision as of publication. https://peptidesciencedaily.com/news/tga-glp-1-naion-eye-disorder-safety-update https://peptidesciencedaily.com/news/tga-glp-1-naion-eye-disorder-safety-update Sat, 25 Jul 2026 09:00:00 GMT Australia's Therapeutic Goods Administration updated product warnings for every GLP-1 receptor agonist sold in the country after adverse-event reports linked the drugs to non-arteritic anterior ischaemic optic neuropathy, a rare condition that can cause permanent vision loss. https://peptidesciencedaily.com/news/fda-panel-votes-peptides-compounding-july-2026 https://peptidesciencedaily.com/news/fda-panel-votes-peptides-compounding-july-2026 Fri, 24 Jul 2026 09:00:00 GMT The Pharmacy Compounding Advisory Committee's two-day vote on seven nominated peptides came over the written objections of the FDA's own career scientists. The recommendations are non-binding, and none of the peptides is an FDA-approved drug. https://peptidesciencedaily.com/news/bmj-glp-1-receptor-agonists-hair-loss-risk-type-2-diabetes https://peptidesciencedaily.com/news/bmj-glp-1-receptor-agonists-hair-loss-risk-type-2-diabetes Thu, 23 Jul 2026 09:00:00 GMT A target trial emulation study of more than 50,000 Penn Medicine patients, published in The BMJ on July 22, 2026, found GLP-1 receptor agonist users had a 37 to 68 percent higher relative risk of clinically recorded hair loss than patients on two other diabetes drug classes, though absolute risk remained low. https://peptidesciencedaily.com/research/attain-j-orforglipron-japan-phase-3-obesity-trial-results https://peptidesciencedaily.com/research/attain-j-orforglipron-japan-phase-3-obesity-trial-results Mon, 20 Jul 2026 09:00:00 GMT Results filed to ClinicalTrials.gov on July 20, 2026 show body weight reductions of up to 8.7 percent at 72 weeks in 238 Japanese adults with obesity, alongside higher rates of gastrointestinal side effects and one death in the highest-dose group. https://peptidesciencedaily.com/news/european-commission-approves-oral-wegovy-semaglutide https://peptidesciencedaily.com/news/european-commission-approves-oral-wegovy-semaglutide Sat, 18 Jul 2026 09:00:00 GMT The July 15, 2026 decision authorizes a once-daily 25 mg semaglutide tablet as the first oral GLP-1 receptor agonist for weight management across the European Union, following a CHMP recommendation adopted in May. https://peptidesciencedaily.com/research/zalfermin-semaglutide-mash-cirrhosis-phase-2-trial https://peptidesciencedaily.com/research/zalfermin-semaglutide-mash-cirrhosis-phase-2-trial Thu, 16 Jul 2026 09:00:00 GMT In a 698-person trial spanning fibrosis stages F2 through compensated cirrhosis, the Novo Nordisk combination did not significantly beat placebo, though semaglutide alone showed a nominal signal, according to results published in The Lancet Gastroenterology & Hepatology on July 15, 2026. https://peptidesciencedaily.com/research/achieve-2-orforglipron-type-2-diabetes-phase-3-trial https://peptidesciencedaily.com/research/achieve-2-orforglipron-type-2-diabetes-phase-3-trial Sun, 12 Jul 2026 09:00:00 GMT In a 40-week trial funded by Eli Lilly, all three tested doses of the oral GLP-1 pill met the study's non-inferiority bar against a standard SGLT2 inhibitor and produced larger average HbA1c reductions, alongside more gastrointestinal side effects and discontinuations. https://peptidesciencedaily.com/research/transcend-trial-setmelanotide-acquired-hypothalamic-obesity https://peptidesciencedaily.com/research/transcend-trial-setmelanotide-acquired-hypothalamic-obesity Sat, 11 Jul 2026 09:00:00 GMT A phase 3 trial published in the New England Journal of Medicine found the approved MC4R agonist lowered BMI by 16.5% over 52 weeks in patients with obesity caused by hypothalamic tumors or injury, versus a 3.3% increase on placebo.